Harvard Bioscience (HBIO) Acquisitions (2010 - 2018)

Harvard Bioscience (HBIO) posted quarterly Acquisitions of $540000.0 for Q4 2018, down 9.24% quarter-over-quarter from $595000.0 in Q2 2018.

Harvard Bioscience (HBIO) Acquisitions (2010 - 2018) Analysis & Trends

Harvard Bioscience (HBIO) has reported Acquisitions for 6 consecutive years, with $540000.0 the latest figure, recorded in Q4 2018.

In Q4 2018, Acquisitions changed N/A year-over-year to $540000.0; the TTM figure through Sep 2019 stood at $540000.0 (down 99.21% YoY), while the FY2018 annual figure was $68.5 million, changed N/A from the prior year.
Acquisitions retreated to $540000.0 in Q4 2018 per HBIO's latest filing, from $595000.0 in the prior quarter.
Across five years, Acquisitions topped out at $67.4 million in Q1 2018 and bottomed at $540000.0 in Q4 2018.
Historically, Acquisitions has averaged $17.1 million across 3 years, with a median of $4.5 million in 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Intuitive Surgical	132.71 Bn	127.50 Bn	1.96 Bn	-
2	Becton Dickinson	51.57 Bn	50.71 Bn	2.32 Bn	22.00 Mn
3	Alcon	35.52 Bn	34.17 Bn	1.68 Bn	-
4	Resmed	33.28 Bn	31.81 Bn	861.22 Mn	325.32 Mn
5	Medline	27.86 Bn	25.18 Bn	2.22 Bn	-
6	West Pharmaceutical Services	25.15 Bn	24.71 Bn	329.20 Mn	-
7	Solventum	15.31 Bn	14.91 Bn	1.29 Bn	-
8	Cooper Companies	14.86 Bn	14.72 Bn	735.40 Mn	-
9	Baxter International	13.63 Bn	11.48 Bn	1.03 Bn	-
10	Harvard Bioscience	34.12 Mn	27.61 Mn	12.63 Mn	-

Download Data